Tata Technologies, Sun Pharma & more: Top stocks on brokers’ radar for July 17, 2025

JP Morgan maintained its underweight rating on Tata Technologies with the target price cut to Rs 570 from Rs 580 earlier. Analysts said the company’s April-June numbers were a mixed one with a beat on revenues while margins were missed. They said deal closures and ramp-ups improved gradually from April to June. They expect the same to continue in July-Sept quarter as clients see the need to restart R&D spends after a period of pause.Goldman Sachs maintained its buy rating on Ola Electric Mobility and hiked the stock’s target price to Rs 63 from Rs 60 earlier. Analysts said that the management gave a flattish guidance for FY26 revenues and 5% auto earnings before interest, taxes, depreciation and amortisation (EBITDA) margin. They also acknowledged management’s efforts in trying to pivot the business towards positive EBITDA and free cash flow breakeven. They expect that the market may need more visibility on volume growth and market share execution.JM Financial initiated its coverage of Kalyan Jewellers with a buy recommendation with the target price at Rs 700. Analysts feel there’s a huge unorganised market providing large growth opportunities for the companies in the sector. They feel moats built earlier by companies will drive future growth. Kalyan Jewellers works on an asset-light mode of store expansion.Citigroup maintained its neutral rating on HCL Technologies with the target price cut to Rs 1,650 from Rs 1,690 earlier. Analysts said the tech major’s April-June earnings before interest and taxes (EBIT) at about 7% was below expectations. The company’s deal pipeline is weak and the overall quarterly result was decent on revenue but light on margins. Analysts said they maintained their cautious view on the sector.Morgan Stanley maintained its overweight rating on Sun Pharmaceuticals with the target price at Rs 1,960. Analysts feel the US launch and settlement for Leqselvi is a positive for the company. The launch, expected in the second half of FY26, happened earlier, supporting the overweight thesis. Project Leqselvi’s expected sales at $61 million for FY26 and $83 million for FY27.Disclaimer: The opinions, analyses and recommendations expressed herein are those of brokerage and do not reflect the views of The Times of India. Always consult with a qualified investment advisor or financial planner before making any investment decisions.